Esperante is a corporate venture capital firm and part of a family-controlled global group with a robust foundation in the pharmaceutical industry. Its leadership is experienced in the development, manufacturing and marketing of prescription pharmaceuticals and in vitro clinical diagnostic tests on a worldwide basis.
Esperante has completed over 25 pharmaceutical and diagnostic company investments in North America, Europe and Israel. 4 exits have been successfully achieved and the fund is currently in profit. 3 portfolio companies, Cara, Medicenna and Altimmune, are listed on the stock exchanges. One therapeutics investment, Cara’s Korsuva, has been approved by the FDA and launched in the US. The remainder are in clinical development phases 2 and 3. Three diagnostics investments have launched in Europe.
Investment strategy
Esperante invests EUR 500,000 to EUR 5,000,000 in syndication with other investors with an exit objective of sale or other liquidity outcomes within a period of 3 years. Our current focus for new investments is on pharmaceutical companies in North America, Europe and Israel entering Phase 2b to Phase 3 clinical development in the following fields:
- Endocrinology
- Fertility
- Gastroenterology
- Gynaecology
- Hepatology
- Infectious disease
- Oncology
- Ophthalmology
- Otology (hearing)
- Urology / uro-oncology
- Women’s health
Esperante does not currently invest in medical devices or digital health technologies and is not currently making new investments in diagnostics whilst continuing to fund its existing diagnostics portfolio companies.
